An observational study in Diastolic Dysfunction, sponsored by Centre d'Investigation Clinique et Technologique 805. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2023-09-08.
Sponsored by Centre d'Investigation Clinique et Technologique 805 · Observational
Myotonic dystrophy type 1 (DM1) is a neuromuscular disorder in relation with an unstable expansion of CTG repeat. Patients with DM1 are at risk of arrhythmia and conduction disorders. Mortality are mainly related to respiratory failure and sudden death. Patients with DM1 may suffer from obesity, arterial hypertension, diabetes mellitus and sleep apnea. These comorbidities are classically associated with left ventricular diastolic dysfunction (DD) .
The investigators aim to assess the prevalence of left ventricular diastolic dysfunction in patients with myotonic dystrophy type 1 , the distribution of DD grading as well as the long-term prognosis of DM1 patients with a left ventricular diastolic dysfunction.
125 studies on the registry are indexed under Myotonic Dystrophy; 51 are open to participants now.
This study's planned enrollment of 500 is above the median of 100 across 56 observational studies indexed under Myotonic Dystrophy.
Browse Myotonic Dystrophy studies →Centre d'Investigation Clinique et Technologique 805 is the lead sponsor of 74 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
patients with myotonic dystrophy type 1 followed in a tertiary reference center.
Exclusion Criteria:
mortality
Time frame: 7 years
Incidence of arrhythmia
Time frame: 7 years
acute heart failure
Time frame: 7 years
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre d'Investigation Clinique et Technologique 805